27-03-2019
Jonathan Weiss / Shutterstock.com
The UK Supreme Court has ruled in favour of Actavis (which has been acquired by Teva) and Mylan in a patent dispute against Eli Lilly, after an earlier court found that one of Eli Lilly’s patents was invalid for lacking an inventive step.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Eli Lilly, Cialis, erectile dysfunction, Teva, Mylan, Actavis, patent validity, UK Supreme Court, Cilias, tadalafil
Eli Lilly avoids sanctions in Teva migraine treatment dispute
13-01-2022
Eli Lilly enters $35m immunology R&D deal
25-04-2019
Eli Lilly defeat shows one size does not fit all in obviousness test: lawyers
28-03-2019
Eli Lilly defeated as Cialis patent found obvious on appeal
01-11-2017
Eli Lilly settles Cialis patent litigation with generic makers
18-07-2017
